BCLI - BRAINSTORM CELL THERAPEUTICS INC.

1.12
-0.030   -2.687%

Share volume: 34,706
Last Updated: 04-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$1.15
-0.03
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
20%
Profitability 0%
Dept financing 30%
Liquidity 15%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.94%
1 Month
-31.29%
3 Months
-46.41%
6 Months
-47.91%
1 Year
53.42%
2 Year
-60.70%
Key data
Stock price
$1.12
P/E Ratio 
0.00
DAY RANGE
$1.11 - $1.27
EPS 
-$0.70
52 WEEK RANGE
$0.20 - $3.71
52 WEEK CHANGE
$92.27
MARKET CAP 
18.363 M
YIELD 
N/A
SHARES OUTSTANDING 
79.734 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
2.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$34,618
AVERAGE 30 VOLUME 
$36,406
Company detail
CEO: Chaim Lebovits
Region: US
Website: brainstorm-cell.com
Employees: 40
IPO year: 2003
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Brainstorm Cell Therapeutics Inc. engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. It is developing NurOwn, which has completed Phase III clinical trial for the. treatment of amyotrophic lateral sclerosis; and Phase II clinical trial. for. progressive multiple sclerosis and alzheimer's disease. The company was formerly known as Golden Hand Resources Inc.

Recent news

Brainstorm Cell Therapeutics Inc (BCLI) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Despite financial constraints, Brainstorm Cell Therapeutics Inc (BCLI) remains committed to advancing its Phase 3b trial for NurOwn, with strategic partnerships and funding avenues in place.

Read more

Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call

Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call

Read more

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update.

Read more